Clinical Study
Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study
Table 3
Change in intensity of symptoms from baseline to each visit for patients from the effectiveness population with moderate to severe LUTS at baseline.
| | At baseline ( = 164) | | Moderate symptoms | Severe symptoms |
| At week 24 ( = 144) | | | ( versus baseline) | | | No symptoms | 0 (0%) | 0 (0%) | Mild symptoms | 34 (23.6%) | 3 (2.1%) | Moderate symptoms | 91 (63.2%) | 10 (6.9%) | Severe symptoms | 1 (0.7%) | 5 (3.5%) | At week 48 ( = 137) | | | ( versus baseline) | | | No symptoms | 1 (0.7%) | 1 (0.7%) | Mild symptoms | 43 (31.4%) | 1 (0.7%) | Moderate symptoms | 75 (54.7%) | 11 (8.0%) | Severe symptoms | 3 (2.2%) | 2 (1.5%) | At last available visit ( = 164) | | | ( versus baseline) | | | No symptoms | 1 (0.6%) | 1 (0.6%) | Mild symptoms | 51 (31.1%) | 2 (1.2%) | Moderate symptoms | 88 (53.7%) | 14 (8.5%) | Severe symptoms | 3 (1.8%) | 4 (2.4%) |
|
|
Bhapkar’s test for homogeneity.
|